Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1âyear of the ACT-SOLO study.

Flipo, René-Marc; Maillefert, Jean-Francis; Chazerain, Pascal; Idier, Isabelle; Coudert, Mathieu; Tebib, Jacques

Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1âyear of the ACT-SOLO study.

Flipo, René-Marc; Maillefert, Jean-Francis; Chazerain, Pascal; Idier, Isabelle; Coudert, Mathieu; Tebib, Jacques.

Afiliación

Flipo RM; Department of Rheumatology , University Hospital , Lille , France.
Maillefert JF; Department of Rheumatology , University Hospital , Dijon , France.
Chazerain P; Department of Rheumatology and Internal Medicine , Croix Saint Simon Hospital , Paris , France.
Idier I; Medical Department , Chugai Pharma , Paris , France.
Coudert M; Department of Clinical Operations , Roche , Boulogne-Billancourt , France.
Tebib J; Department of Rheumatology , Lyon Sud hospital , Lyon , France.

RMD Open ; 3(1): e000340, 2017.

Article en En | MEDLINE | ID: mdl-28123778

Palabras clave

DMARDs (biologic); Epidemiology; Rheumatoid Arthritis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Qualitative_research Idioma: En Revista: RMD Open Año: 2017 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google